Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $92

Stifel analyst Alex Thompson has maintained a 'Buy' rating on Spyre Therapeutics (NASDAQ: SYRE) and increased the price target from $70 to $92. This adjustment reflects a positive outlook for the company's performance in the market.